- About Us
- Continuing Nursing Education CNE - Goodfellow Unit
- Continuing Nursing Education (CNE) Template
- Endorsement Application Form
- Guidelines and Professional Position statements
- Links of Interest
- National Nursing Consortium
- National Nursing Organisations Leaders Group Repository
- Nursing Praxis in NZ
- Nursing Review
- Professional Support Guides
- Te Puawai - Read Online
- Te Puawai Archives
- Meet the Executive
- Social Media
- Terms of Reference
- Members List
- NPNZ Forum
- NPNZ Executive Forum
- What is a NP?
- Do you want to become an NP in New Zealand?
- Information for Employers
- Examples of NP Job Descriptions & Business Case Proposals
- Supervisors for NP Interns Resource Toolkit
- Conferences & Events
- NPNZ Minutes -members only
- NPNZ Useful Documents
- NP Resources
- Join NPNZ
Webinar Invite: Palbociclib (Ibrance) for advanced ER+ breast canceron 13 March
Palbociclib (Ibrance) for metastatic ER+ breast cancer – NZ update
When: Monday, 19th March 2018
What time: 1:30pm - 2:30pm NZDT
Where: Online - join via your computer!
Your Hosts: Breast Cancer Foundation NZ with Dr Richard Finn
About the Webinar
Palbociclib (brand name Ibrance) is a new medicine for advanced ER+ breast cancer that has achieved significant results in high-profile clinical trials overseas. It’s not funded in New Zealand, but some Kiwis have been buying it off-shore, and there will soon be compassionate access for NZ patients that will make it potentially more affordable.
Meet your panel:
- Dr Richard Finn is associate professor of Medicine at the UCLA David Geffen School of Medicine. He led the PALOMA series of clinical trials for palbociclib and is considered one of the world’s foremost experts on this new drug.
What will you get out of this session?
This session will give you a run-down on what palbociclib is, how it works and who for; where it sits among treatments for advanced ER+ breast cancer; opportunities in NZ for clinical trials and compassionate access to palbociclib; paying privately, and discussing palbociclib with your oncologist